Overview

Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The study will determine the magnitude and duration (time to resolution i.e., returning to normal ranges) of elevations in the following coagulation test results after a single 1200 mg dose of oritavancin: Prothrombin Time/International Normalized Ratio (PT/INR), Activated clotting time (ACT), Activated Partial Thromboplastin Time (APTT), Chromogenic Factor Xa Assay, D-dimer, Silica Clot Time and Dilute Russell's Viper Venom Time (DRVVT).
Phase:
Phase 1
Details
Lead Sponsor:
The Medicines Company
Collaborator:
Christchurch Clinical Studies Trust Ltd
Treatments:
Oritavancin